Oxemia 50 Tablet contains Desidustat 50 mg, a potent hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) indicated for the treatment of anemia associated with chronic kidney disease (CKD). Desidustat acts by stabilizing hypoxia-inducible factors, thereby stimulating endogenous erythropoietin production and enhancing erythropoiesis. This mechanism helps improve hemoglobin levels and reduces the need for exogenous erythropoiesis-stimulating agents (ESAs). Oxemia 50 is particularly beneficial for patients undergoing dialysis as well as those with non-dialysis-dependent CKD. The tablet is administered orally, offering a convenient alternative to injectable therapies. Clinical studies have demonstrated its efficacy in increasing hemoglobin concentrations while maintaining a favorable safety profile. Common adverse effects may include mild gastrointestinal disturbances, headache, and hypertension, though these are generally manageable. Oxemia 50 should be used under medical supervision, with regular monitoring of hemoglobin levels, blood pressure, and iron parameters to optimize therapeutic outcomes and minimize risks. It is contraindicated in patients with uncontrolled hypertension or hypersensitivity to Desidustat or any excipients. Overall, Oxemia 50 Tablet represents an effective and well-tolerated option for managing anemia in CKD, improving patient quality of life and reducing dependence on injectable treatments.